+86-28-82633987
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
32.7000
2.0500
2.0500
High
No
No
No
No
No
No
Natural products, as important sources of drug discovery, have attracted much attention due to their structural diversity and biological activity. 1-Cinnamoylpyrrolidine is a natural small molecule isolated from Piper caninum, and in recent years, its unique pharmacological activity has attracted widespread research interest. This compound exhibits DNA strand cleavage activity, inducing the relaxation of plasmid DNA supercoils in the presence of copper ions, and significantly inhibits platelet aggregation induced by platelet activating factor (PAF), demonstrating potential antibacterial, anticancer, antithrombotic, and anti-inflammatory multiple pharmacological effects. This paper provides a systematic review of the chemical structure, origin, pharmacological activity, mechanism of action, and druggability evaluation of 1-cinnaylpyrrolidin, aiming to provide a theoretical foundation and research direction for its further drug development and clinical application.
The molecular formula of 1-cinnaylpyrrolidine is C13H15NO, with a molecular weight of 201.27. Its structure consists of a pyrrolidone ring connected by a cinnamoyl group via a nitrogen atom, exhibiting typical amide bond characteristics. This structure contains both aromatic conjugated systems and the saturated ring structure of pyrrolidin, giving it good molecular stability and moderate polarity.
In terms of physicochemical properties, the LogP value of 1-cinnaylpyrrolidine is about 2.05, indicating moderate lipid solubility, which is beneficial for cell membrane penetration and bioavailability. The polar surface area (TPSA) is 32.7 Ų, and the number of hydrogen bond acceptors is 2, indicating that it possesses certain hydrogen bonding ability in intermolecular interactions. This compound has high blood-brain barrier penetration potential and shows no hepatotoxicity, cardiotoxicity, hERG channel inhibition, or genotoxicity (Ames test negative), demonstrating a good safety and druggability foundation.
1-cinnaylpyrrolidine is mainly isolated from crude extracts of Piper caninum, a plant in the piperaceous family. Piper plants are widely distributed in tropical and subtropical regions and have long been used as traditional medicinal herbs, rich in bioactive components. The extraction of this compound typically uses organic solvents (such as methanol, ethanol, or ethyl acetate) to extract dry plant powders, followed by separation and purification techniques such as liquid-liquid separation, column chromatography, and high-performance liquid chromatography (HPLC) to obtain the pure product.
Optimizing the extraction process is crucial for improving the yield and purity of 1-cinnaylpyrrolidin. In recent years, the application of modern extraction technologies such as ultrasound-assisted extraction and microwave-assisted extraction is expected to further improve extraction efficiency and environmental friendliness. In addition, the sustainability of plant-derived materials and the stability of compounds are also key factors to consider during preparation.
1-Cinnaylpyrrolidine exhibits certain inhibitory effects on various bacteria and fungi. Its targets include key enzymes such as bacterial DNA gyrase (GYRA), cell wall synthase (FABI), and dihydrofolate reductase (DHFR), indicating that it may achieve antibacterial effects by interfering with bacterial DNA replication and cell wall synthesis. Additionally, its effects on fungal-related targets such as ERG11 and CYP51A1 suggest its antifungal potential.
As a DNA strand breaker, 1-cinnaylpyrrolidine can induce superspirinal relaxation of plasmid pBR322 DNA in the presence of copper ions, suggesting it may exert antitumor effects by mediating DNA damage. Its targets include DNA topoisomerase I (TOP1) and II (TOP2A), both of which play key roles in DNA replication and transcription, making them important targets for various anticancer drugs. Additionally, this compound may affect the signaling pathways of tumor suppressor protein p53 (TP53) and nuclear factor κB (NFKB1), regulating apoptosis and inflammatory responses, further enhancing its anticancer potential.
1-Cinnaylpyrrolidine can effectively inhibit platelet aggregation induced by platelet-activating factor (PAF), with an IC50 of about 37.3 μM. Its main target is the platelet-activating factor receptor (PTAFR), and it may also affect key factors such as the platelet glycoprotein IIb/IIIa complex (ITGA2B/ITGB3) and thrombin (F2), blocking platelet aggregation and thrombosis processes, and has potential antithrombotic therapeutic value.
By inhibiting inflammation-related targets such as platelet-activating factor receptor (PTAFR), cyclooxygenase-2 (PTGS2), nuclear factor κB (NFKB1), and tumor necrosis factor α (TNF), 1-cinnamylpyrrolidone exhibits significant anti-inflammatory effects. It may reduce the production and release of inflammatory mediators by blocking inflammatory signaling pathways, thereby alleviating inflammatory responses and making it suitable for treating inflammatory diseases.
Although research on 1-cinnamylpyrrolidone in neurodegenerative diseases is limited, its good blood-brain barrier penetration and potential regulatory ability to neuropathological targets such as β-amyloid precursor protein lyase (BACE1) and tau protein (MAPT) suggest that its application prospects in neurodegenerative diseases like Alzheimer's are worth further exploration.
The multi-target mechanism of 1-cinnaylpyrrolidines forms the basis for its multiple pharmacological activities. Its DNA strand cleavage activity mainly relies on copper ion-mediated oxidative stress responses, leading to relaxation and breakage of DNA superhelix structures, interfering with tumor cell proliferation and survival. Inhibition of DNA topoisomerase further blocks DNA replication and transcription, inducing apoptosis.
In terms of antithrombotic and anti-inflammatory effects, 1-cinnamylpyrrolidone competitively or non-competitively binds to platelet-activating factor receptors, inhibiting PAF-mediated signaling and reducing platelet aggregation and inflammatory mediator release. Additionally, its inhibitory effect on cyclooxygenase-2 and nuclear factor κB reduces the expression of prostaglandins and pro-inflammatory cytokines, thereby alleviating inflammatory responses.
Its antibacterial effect involves inhibiting key bacterial enzymes, blocking bacterial DNA replication, cell wall synthesis, and metabolic processes, thereby inhibiting bacterial growth and reproduction. The effect on fungal targets may disrupt the integrity of fungal cell membranes by interfering with sterol biosynthesis pathways.
1-Cinnaylpyrrolidine has a moderate molecular weight (201.27 Da), meeting the requirements of the Lipinski Five Rules. The LogP value is 2.05, indicating good lipid solubility, which is beneficial for oral absorption and cell membrane penetration. The TPSA is 32.7 Ų, far below the blood-brain barrier penetration threshold of 140 Ų. Combined with its high blood-brain barrier permeability, it demonstrates its potential for application in central nervous system diseases.
In terms of safety, this compound shows no hepatotoxicity, cardiotoxicity, or hERG channel inhibition, and the Ames test was negative, indicating a low genotoxicity risk and a solid safety foundation. Preliminary pharmacokinetic studies show that it has moderate bioavailability and in vivo stability, but its specific absorption, distribution, metabolism, and excretion (ADME) characteristics still require further systematic study.
Based on its multi-target and multi-effect pharmacological properties, 1-cinnamylpyrrolimine shows broad application prospects in anti-cancer, antithrombotic, antibacterial, and anti-inflammatory fields. Especially in tumor treatment, its dual mechanism of action as both a DNA strand breaker and a topoisomerase inhibitor makes it a promising candidate molecule for novel anticancer drugs.
Moreover, its inhibitory effect on platelet-activating factor receptors offers new ideas for the prevention and treatment of thrombotic diseases. Anti-inflammatory activity offers a potential option for treating chronic inflammatory diseases. Given its excellent blood-brain barrier penetration, future research in the field of neurodegenerative diseases deserves special attention.
However, preclinical and clinical research on 1-cinnaylpyrrolidine are still in their early stages. In the future, systematic research on its pharmacokinetics, toxicology, and pharmacodynamics needs to be strengthened, its structure optimized to improve activity and selectivity, suitable dosing formulations developed, and related clinical trials conducted to verify its safety and efficacy.
1-Cinnaylpyrrolidin, a natural product derived from Piper caninum, demonstrates broad drug development potential due to its unique chemical structure and diverse pharmacological activities. Its multi-target mechanisms in fields such as anticancer, antithrombotic activity, antibacterial, and anti-inflammatory have provided valuable examples for pharmacological research of natural products. In the future, through in-depth mechanistic research and preclinical evaluation, it is expected to promote its translation into clinical applications, becoming a new generation of natural drug candidate molecules with multiple therapeutic functions.
Shenshuai
Wenjing
Hedandan
